Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,897 Mln
Revenue (TTM)
$137 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
205.7
Industry P/E
--
EV/EBITDA
-12.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
63,621,500
CFO
$-829.54 Mln
EBITDA
$-938.69 Mln
Net Profit
$-852.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
| 14.1 | 3.4 | 10.1 | 68.3 | 173.6 | 27.0 | -- |
|
BSE Sensex*
| 4.3 | 3.9 | 7.7 | 10.2 | 14.5 | 21.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
| 21.6 | 57.9 | 191.8 | -66.4 | 29.5 | -14.6 | -7.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
|
63.9 | 3,896.8 | 136.9 | -170.0 | -110.5 | -195.1 | -- | 205.7 |
| 49.5 | 7,725.5 | 1,208.8 | 131.7 | 13.4 | 6.3 | 59.4 | 3.8 | |
| 103.0 | 6,536.7 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 19.1 | |
| 143.5 | 6,944.0 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.2 | |
| 57.8 | 10,741.1 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.4 | |
| 44.4 | 12,187.3 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20.4 | 5.8 | |
| 53.5 | 6,410.0 | 1,084.3 | 485.4 | 57.0 | 103.8 | 13.8 | 13.3 | |
| 306.6 | 8,785.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.3 | 14.8 | |
| 28.0 | 10,206.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 123.0 | 12,155.0 | 2,412.6 | 305.8 | 20.5 | 11.6 | 41.6 | 4.7 |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of... pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116 Read more
Chairman, President & CEO
Dr. David P. Meeker M.D.
Chairman, President & CEO
Dr. David P. Meeker M.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Rhythm Pharmaceuticals Inc (RYTM) stood at $ 499 Mln as on 31-Mar-25
The share price of Rhythm Pharmaceuticals Inc (RYTM) is $63.87 (NASDAQ) as of 20-May-2025 16:04 EDT. Rhythm Pharmaceuticals Inc (RYTM) has given a return of 173.56% in the last 3 years.
Rhythm Pharmaceuticals Inc (RYTM) has a market capitalisation of $ 3,897 Mln as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Rhythm Pharmaceuticals Inc (RYTM) is 205.67 times as on 20-May-2025, a 9291% premium to its peers’ median range of 2.19 times.
Since, TTM earnings of Rhythm Pharmaceuticals Inc (RYTM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rhythm Pharmaceuticals Inc (RYTM) and enter the required number of quantities and click on buy to purchase the shares of Rhythm Pharmaceuticals Inc (RYTM).
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116
The CEO & director of Dr. David P. Meeker M.D.. is Rhythm Pharmaceuticals Inc (RYTM), and CFO & Sr. VP is Dr. David P. Meeker M.D..
There is no promoter pledging in Rhythm Pharmaceuticals Inc (RYTM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| Rhythm Pharmaceuticals Inc. (RYTM) | Ratios |
|---|---|
|
Return on equity(%)
|
-195.09
|
|
Operating margin(%)
|
-110.51
|
|
Net Margin(%)
|
-124.23
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Rhythm Pharmaceuticals Inc (RYTM) was $0 Mln.
$2.62
(
